Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases.
作者信息
Cozzani Emanuele, Gasparini Giulia, Sticchi Laura, Russo Roberto, Icardi Giancarlo, Parodi Aurora
机构信息
Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, Dermatology Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy.
Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, Dermatology Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy, Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
出版信息
Eur J Dermatol. 2021 Jun 1;31(3):415-417. doi: 10.1684/ejd.2021.4043.
Abstract
摘要
相似文献
1
Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases.自身免疫性水疱病患者接种新型冠状病毒疫苗的考量
Eur J Dermatol. 2021 Jun 1;31(3):415-417. doi: 10.1684/ejd.2021.4043.
2
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是否会影响自身免疫性水疱病的免疫抑制治疗？
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e295-e297. doi: 10.1111/jdv.16491.
3
Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.自身免疫性疾病患者暂停免疫抑制治疗可改善对SARS-CoV-2疫苗的免疫反应：一例报告
Ann Rheum Dis. 2021 Oct;80(10):1359-1361. doi: 10.1136/annrheumdis-2021-220993. Epub 2021 Jul 16.
4
Azathioprine in the treatment of autoimmune blistering diseases.硫唑嘌呤治疗自身免疫性水疱病。
Immunol Allergy Clin North Am. 2012 May;32(2):295-307, vii-viii. doi: 10.1016/j.iac.2012.04.009.
5
[COVID-19 vaccines and cancer patients: State of the art and guidelines summary].[新型冠状病毒肺炎疫苗与癌症患者：最新进展及指南总结]
Bull Cancer. 2021 May;108(5):553-555. doi: 10.1016/j.bulcan.2021.03.008. Epub 2021 Apr 8.
6
In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.简而言之：为免疫功能低下者接种第三剂基于mRNA的新冠疫苗。
Med Lett Drugs Ther. 2021 Sep 20;63(1633):145-146.
7
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].[多发性硬化症患者的新型冠状病毒2型疫苗接种]
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
8
[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].正在接受治疗的癌症患者必须立即遵守抗SARS-CoV-2疫苗接种计划。
Bull Cancer. 2021 Apr;108(4):341-342. doi: 10.1016/j.bulcan.2021.02.003. Epub 2021 Mar 5.
9
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.COVID-19 疫苗接种在自身免疫性炎症性风湿病患者中的应用：韩国风湿病学会的临床指南。
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.
10
SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.严重急性呼吸综合征冠状病毒2与风湿病患者：过去12个月及未来展望
Ann Rheum Dis. 2021 Oct;80(10):1249-1251. doi: 10.1136/annrheumdis-2021-221251.
引用本文的文献
1
Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report.巴西新冠疫情期间自身免疫性水疱病患者免疫接种与免疫抑制的考量：病例报告
Front Med (Lausanne). 2022 Apr 12;8:811562. doi: 10.3389/fmed.2021.811562. eCollection 2021.
2
Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset.解除新冠疫苗接种与自身免疫性大疱病发病的关联
Front Immunol. 2022 Feb 18;13:834316. doi: 10.3389/fimmu.2022.834316. eCollection 2022.
3
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.天疱疮患者的 COVID-19 严重程度和 SARS-CoV-2 疫苗安全性。
Dermatol Ther. 2022 May;35(5):e15417. doi: 10.1111/dth.15417. Epub 2022 Mar 10.
本文引用的文献
1
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
2
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
4
Bullous Pemphigoid: Trigger and Predisposing Factors.大疱性类天疱疮：触发因素和易感因素。
Biomolecules. 2020 Oct 10;10(10):1432. doi: 10.3390/biom10101432.
5
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.COVID-19 疫苗 BNT162b1 可引发人体抗体和 T1 T 细胞应答。
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.
6
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.奥瑞珠单抗对多发性硬化症患者疫苗反应的影响：VELOCE 研究。
Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.
7
Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity.致病性预激发可能通过自身免疫导致新冠病毒病的严重和危重症以及死亡。
J Transl Autoimmun. 2020 Apr 9;3:100051. doi: 10.1016/j.jtauto.2020.100051. eCollection 2020.
8
Treatment considerations for patients with pemphigus during the COVID-19 pandemic.COVID-19大流行期间天疱疮患者的治疗考量
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236. doi: 10.1016/j.jaad.2020.04.005. Epub 2020 Apr 10.
9
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.2019 年更新版：欧洲抗风湿病联盟成人自身免疫性炎症性风湿病患者疫苗接种推荐。
Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.
10
Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses.基于文献的针对自身免疫性大疱性皮肤病需要免疫抑制药物治疗患者的免疫接种建议。
Int J Dermatol. 2016 Jun;55(6):599-607. doi: 10.1111/ijd.13140. Epub 2015 Dec 29.
Zotero 插件